补肺平喘方联合沙美特罗替卡松治疗肺肾气虚型慢性阻塞性肺疾病稳定期临床研究  

Clinical Study on Bufei Pingchuan Prescription Combined with Salmeterol Fluticasone for Chronic Obstructive Pulmonary Disease of Lung-Kidney Qi Deficiency Type at Stable Stage

作　　者：姚云丹 黄达荣 许丽佳[2] YAO Yundan;HUANG Darong;XU Lijia

机构地区：[1]浙江中医药大学,浙江杭州310053 [2]杭州市余杭区中医院呼吸内科,浙江杭州311106

出　　处：《新中医》2021年第24期80-83,共4页New Chinese Medicine

摘　　要：目的:观察补肺平喘方联合沙美特罗替卡松治疗肺肾气虚型慢性阻塞性肺疾病(COPD)稳定期的临床疗效。方法:选取100例肺肾气虚型COPD稳定期患者,按随机数字表法分为治疗组和对照组各50例。2组均给予常规对症治疗,对照组在此基础上给予沙美特罗替卡松吸入粉雾剂吸入治疗,治疗组在对照组基础上给予补肺平喘方治疗,2组均治疗2个月。比较2组临床疗效、中医证候积分、肺功能及免疫功能。结果:治疗组总有效率为94.00%,较对照组的70.00%高(P<0.05)。治疗后,治疗组中医证候积分低于对照组(P<0.05);治疗组第1秒用力呼气容积(FEV_(1))、用力肺活量(FVC)、第1秒用力呼气容积占预计值百分比(FEV_(1)%pred)及免疫球蛋白M(IgM)、免疫球蛋白G(IgG)、免疫球蛋白A(IgA)水平均高于对照组(P<0.05)。结论:补肺平喘方联合沙美特罗替卡松治疗肺肾气虚型COPD稳定期能有效缓解患者的临床症状,改善其肺功能,提高机体免疫力。Objective:To observe the clinical effect of Bufei Pingchuan prescription combined with salmeterol fluticasone for chronic obstructive pulmonary disease(COPD)of lung-kidney qi deficiency type at stable stage.Methods:A total of 100 cases of COPD patients of lung-kidney qi deficiency type at stable stage were selected and divided into the treatment group and the control group according to the random number table method,with 50 cases in each group.Both groups were given routine symptomatic treatment;the control group was additionally given the inhalation treatment with salmeterol fluticasone powder,and the treatment group was additionally treated with Bufei Pingchuan prescription based on the treatment of the control group.Both groups were treated for two months.The clinical effects,Chinese medicine syndrome scores,lung function indexes and immune function indexes in the two groups were compared.Results:The total effective rate was 94.00%in the treatment group,higher than that of 70.00%in the control group(P<0.05).After treatment,Chinese medicine syndrome score in the treatment group was decreased when compared with that in the control group(P<0.05);the levels of forced expiratory volume in one second(FEV_(1)),forced vital capacity(FVC),immunoglobulin M(IgM),immunoglobulin G(IgG)and immunoglobulin A(IgA)and the values of FEV_(1)/%pred in the treatment group were increased when compared with those in the control group(P<0.05).Conclusion:The therapy of Bufei Pingchuan prescription combined with salmeterol fluticasone has a definite curative effect in treating COPD of lung-kidney qi deficiency type at stable stage,which can effectively relieve the clinical symptoms of patients,improve their lung function,and enhance the body immunity.

关 键 词：慢性阻塞性肺疾病 稳定期 肺肾气虚型 补肺平喘方 沙美特罗替卡松 中医证候 肺功能 免疫功能 

分 类 号：R563[医药卫生—呼吸系统]